Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 16, 2023, the Board of Directors (the "Board") of Medpace Holdings,
Inc. (the "Company"), following a recommendation from the independent directors
of the Board, unanimously approved that Dr. Femida H. Gwadry-Sridhar be elected
to fill the Class I director vacancy on the Board of the Company, effective
January 16, 2023, and that Dr. Gwadry-Sridhar shall hold such position as a
Class I director until the 2023 Annual Meeting of Stockholders and until her
successor is duly elected and qualified or until her earlier death, resignation
or removal. Dr. Gwadry-Sridhar is expected to be appointed to the Nominating and
Governance Committee.
Dr. Gwadry-Sridhar is the Founder and Chief Executive Officer of Pulse Infoframe
Inc, a privately held real-world evidence generation platform company providing
solutions for disease registries, natural history studies and other
observational and regulatory grade studies since 2011. During her career she has
held academic appointments at Western University and as a visiting Professor at
the University of Southern California. Dr. Gwadry-Sridhar is considered a
thought leader in real-world evidence with over 220 publications in top tier
journals, recognition as a career scientist and lifetime fellow of the Canadian
Institute of Health Research (CIHR), and as a founding member of the medical
adherence group at the Society for Pharmacoeconomics and Outcomes Research
(ISPOR). She has been recognized as and supports female entrepreneurs in digital
health and has served on numerous community and non-profit boards. She is also a
Director of Pulse Infoframe Inc. and Pulse Infoframe US, LLC.
Dr. Gwadry-Sridhar received a B.S. Biology from Western University, a B.Sc.Phm.
from University of Toronto, a M.Sc. (epi) from Western University and Ph.D. in
health research methodology from McMaster University.
Dr. Gwadry-Sridhar will participate in the Company's standard compensation
program for non-employee directors. On January 16, 2023, Dr. Gwadry-Sridhar was
granted an equity award in the form of an option to purchase 573 shares of the
Company's common stock with an exercise price equal to the closing price per
share of the Company's common stock on January 13, 2023, the last preceding
trading day because the date of Dr. Gwadry-Sridhar's election was not a trading
day, and a term of seven years. The Company has entered into the Company's
standard indemnification agreement for directors and officers with
Dr. Gwadry-Sridhar.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses